INOVIO PHARMACEUTICALS Forum: Community User: gerry

INOVIO Second Quarter Highlights - INO-4800 U.S. Phase 1 clinical manuscript with full clinical data currently under-going peer-review for publication at a top medical journal; INO-4800 was generally safe and well-tolerated in all participants with only 6 treatment related Grade 1 (lowest) AEs - 100% of trial participants demonstrated overall immune responses - 95% had seroconverted by antibody response overall; - Nearly 90% generated strong T cell responses, including CD8+ T cell responses - Secured $71 million from U.S. Department of Defense to scale up manufacture of CELLECTRA® 3PSP smart device and procurement of CELLECTRA® 2000 - Reported favorable INO-4800 animal challenge data in mouse and non-human primate (NHP) studies; NHP challenge data at 13 weeks post last immunization showed robust memory immune responses and protection from virus replication in both nasal passages and lower lungs - INO-4800 selected by U.S. Operation Warp Speed for COVID-19 non-human primate challenge study - Expanded INO-4800 DNA manufacturing agreement with Richter-Helm and CEPI to support large-scale manufacturing; currently expanding manufacturing consortium and on track to meet goal of producing at least 100 million INO-4800 doses in 2021 via growing global coalition of partners and funders - Phase 1/2 INO-4800 trials for COVID-19 approved in South Korea and China - Presented positive 12-month overall survival efficacy data demonstrating 85% survival rate for DNA immunotherapy candidate INO-5401 in treatment of glioblastoma multiforme (GBM) at American Society of Clinical Oncology (ASCO) Annual Meeting - Reported positive Interim Phase 2 results for DNA immunotherapy candidate VGX-3100 in treating HPV-associated anal and vulvar dysplasia; VGX-3100 REVEAL 1 pivotal Phase 3 data for HPV-associated cervical dysplasia on track to be reported in 4Q2020 - INO-3107, a treatment of recurrent respiratory papillomatosis (RRP), a rare, debilitating disease caused by HPV infection, received Orphan Disease designation by the FDA; Phase 1/2 clinical trial initiated Investor Call Today at 4:30 PM ET

Aua das wird teuer

FAC das ist ja alles bekannt was du reingestellt hast der Markt möchte immer noch News hören. Haben die da nichts dabei

Aua 15€ 🙈

Die wollen das du verkaufst

Warum sackt der Kurs Nachbörslich total ab???

Versteh das nicht. Shit

Naja wird schon 😜

Gute Zahlen, eigentlich... jetzt wird manipuliert

Jetzt gehts richtig runter 🙈

Jetzt - 9 % 18,40$

Mein Link funktioniert auch nicht😏

On June 3, 2020, we filed a complaint in the Court of Common Pleas of Montgomery County, Pennsylvania against VGXI, Inc. and GeneOne Life Science, Inc., collectively referred to as VGXI, alleging that VGXI had materially breached our supply agreement with them. The complaint seeks declaratory judgments, specific performance of the agreement, injunctive relief, an accounting, damages, attorneys’ fees, interest, costs and other relief from VGXI. On June 3, 2020, we filed a petition for preliminary injunction, which was denied on June 25, 2020. On June 26, 2020, we filed notice of appeal of the denial of the petition with the Pennsylvania Superior Court. On July 7, 2020, VGXI filed an answer, new matter and counterclaims against us, alleging that we had breached the supply agreement, as well as misappropriation of trade secrets and unjust enrichment. The counterclaims seek injunctive relief, damages, attorneys’ fees, interest, costs and other relief from us. Also, on July 7, 2020, VGXI filed a third-party complaint against Ology Bioservices, Inc., a contract manufacturing organization that we had engaged to provide services similar to those that were being provided by VGXI. On July 27, 2020, we filed an answer to VGXI’s counterclaims, disputing the allegations and the claims raised in VGXI’s filing. A trial date for the litigation has not been set. We intend to aggressively prosecute the claims set forth in our complaint against VGXI and to vigorously defend ourselves against VGXI’s counterclaims.

Kann sich Longie durchlesen der versteht das😉😂😂

http://d18rn0p25nwr6d.cloudfront.net/CIK-0001055726/952770fd-3b6b-47c0-b357-0bed3f628b83.pdf

Super, muss mir das erstmal auf Deutsch übersetzen muss ich morgen wohl krank machen das ich alles lesen kann 🤣🤣🤣